Prognostic value of the expression of p53, bcl-2, and box oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2456-2466

  Apolinario, Rosa M ^a   van der Valk, Paul ^a   de Jong, Johannes S ^a   Deville, Walter ^a   van Ark Otte, Jannette ^a   Dingemans, Anne Marie C ^a   van Mourik, Johan C ^a   Postmus, Piet E ^a   Pinedo, Herbert M ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 0030940210     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2456     Document Type: Article

References (56)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1994. CA 44:7-26, 1994
2. Mountain CF: A new international staging system for lung cancer. Chest 89:225-323, 1986 (suppl)
3. Lee JS, Hong WK: Prognostic factors in lung cancer. N Engl J Med 327:47-48, 1992
4. Chiba I, Takahashi T, Nau MM, et al: Aberrations of the p53 tumor suppressor gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610, 1990
5. Kishimoto Y, Murakami Y, Shiraishi M, et al: Aberrations of the p53 tumor suppressor gene in human non-small cell lung carcinomas of the lung. Cancer Res 52:4799-4804, 1992
6. Mitsudomi T, Oyama T, Kusano T, et al: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85:2018-2023, 1993
7. Marchetti A, Buttitta F, Merlo G, et al: p53 alterations in non small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846-2851, 1993
8. Horio Y, Takahashi T, Kuroishi T, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non small cell lung cancer. Cancer Res 53:2846-2851, 1993
9. Carbone DP, Mitsudomi T, Chiba I, et al: p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest 106:377S-381S, 1994 (suppl)
10. Cleary MI, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl2/immunoglobulin transcript resulting from the t(14;18) transcription. Science 226:1097-1099, 1994
11. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G: Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 145:1036-1040, 1994
12. Fontanini G, Vignati S, Bigini D, et al: bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71:1003-1007, 1995
13. Walker C, Robertson L, Myskow M, et al: Expression of bcl-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 72:164-169, 1995
14. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989
15. Kieser A, Weich HA, Bradner G, et al: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 10:2207-2212, 1994
16. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994
17. World Health Organization: The World Health Organization histological typing of lung cancer. Am J Clin Pathol 77:123-136, 1982
18. Pezzella F, Turley H, Kuzu I, et al: bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329:690-694, 1993
19. Kuiper CM, Broxterman HJ, Baas F, et al: Drug transport variants without p-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubucin. J Cell Pharmacol 1:35-41, 1990
20. Krajewski S, Krejewska M, Shabaik A, et al: Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 145:1323-1336, 1994
21. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis. A new significant and independent prognostic factor in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
22. Norusis MJ: SPSS for Windows: Advanced statistics, release 6.0. Chicago, IL, SPSS Inc, 1993
23. Strauss GM, Kwiatkowski DJ, Harpole DH, et al: Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13:1265-1279, 1995
24. Top B, Mooi WJ, Klaver SG, et al: Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 64:83-91, 1995
25. Mitsudomi T, Steinberg SM, Nau MM, et al: p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180, 1992
26. Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor. J Clin Oncol 13:1893-1903, 1995
27. Passlick B, Izbicki JR, Riethmuller G, et al: p53 in non-small cell lung cancer. J Natl Cancer Inst 86:801-802, 1994
28. Brambilla E, Gazzeri S, Moro D, et al: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-220, 1993
29. McLaren R, Kuzu I, Dunnill M, et al: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738, 1992
30. Sjogren S, Inganas M, Norberg T, et al: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996
31. Ebina M, Steinberg SM, Mulshine JL, et al: Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496-2503, 1994
32. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992
33. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
34. Nishio M, Koshikawa T, Kuroishi T, et al: Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14:497-502, 1996
35. Joensuu H, Pylkkanen L, Toikkanen S: bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198, 1994
36. Lipponen P, Eskelinen M, Syrjanen K: Expression of tumor-suppressor gene Rb, apoptosis-suppressing protein bcl-2 and c-myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 71:863-867, 1995
37. Mc Donell TJ, Deane N, Platt FM, et al: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follycular lymphoproliferation. Cell 57:79-88, 1989
38. Hellemans P, van Dam PA, Weyler J, et al: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72:354-360, 1995
39. Silvestrini R, Veneroni S, Daidone MG, et al: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
40. Gasparini G, Barbareschi M, Doglioni C, et al: Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
41. Gorezyca W, Markiewski M, Kram A, et al: Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: Their correlation with Ki-67 growth fraction. Virchows Arch 426:229-233, 1995
42. Haldar S, Negrini M, Monne M, et al: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097, 1994
43. Sinicrope FA, Ruan SB, Cleary KR, et al: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237-241, 1995
44. Pezzella F, Morrison H, Jones M, et al: Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 22:39-44, 1993
45. Tormanen U, Aerola A-K, Rainio P. et al: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55:5595-5602, 1995
46. Cory S: Regulation of lymphocyte survival by the bcl-2 gene family. Ann Rev Immunol 13:513-543, 1995
47. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
48. Oltavai ZN, Millman CL, Korsmeyer SJ: bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74:609-619, 1993
49. Xu HJ, Quinlan DC, Davidson AG, et al: Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 86:695-699, 1994
50. Quinlan DC, Davidson AS, Summers CL, et al: Accumulation of p53 correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
51. Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042, 1995
52. Krajewski S, Blomqvist C, Franssila K, et al: Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast cancer. Cancer Res 55:4471-4478, 1995
53. Macchiarini P, Fontanini G, Hardin MJ, et al: Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 340:145-146, 1992
54. Westra WH, Offerhaus JA, Goodman SN, et al: Overexpression of p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 17:213-220, 1993
55. Mørkve O, Halvorsen OJ, Skjaerrven R, et al: Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 13:571-578, 1993
56. Kashii T, Mizushima Y, Lima CEQ, et al: Studies on clinicopathological features of lung cancer patients with k-ras/p53 gene alterations: Comparison between younger and older groups. Oncology 52:219-225, 1995